Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

PACB vs VVOS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PACB Captures Overall Composite Edge (50.1 HOLD vs 36.4 SELL), While VVOS Leads 3–2 on Growth & Valuation Pillars

PACB Overall Winner 6-Pillar Tally: PACB 2 – 3 VVOS (1 Tie) Matrix Metrics: PACB 6 – 2 VVOS

As of Nov 20, 2026, Pacific Biosciences of California, Inc. (PACB) captures the overall head-to-head institutional edge over Vivos Therapeutics, Inc. (VVOS) on higher Unified Composite conviction (50.1/100 HOLD vs. 36.4/100 SELL) after splitting the core matrix 6–2 (led by Growth & Scale, Options & Positioning), while VVOS wins 3–2 across the 6-pillar growth and valuation breakdown. PACB trades at $1.63 (N/M Forward P/E, -333.0% operating margin) versus VVOS at $0.05 (N/M Forward P/E, -107.9% operating margin).

  • Growth vs. Quality Trade-Off: PACB earns the overall head-to-head edge with a stronger Unified Composite Score (50.1/100 HOLD vs. VVOS 36.4/100 SELL) and 2.25β · 104% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: PACB is currently in a Breakdown options structure phase (RSI 35.4); meanwhile VVOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PACB vs VVOS
PACB NASDAQ Head-to-Head Winner
Pacific Biosciences of California, Inc.
Laboratory Analytical Instruments
$1.63
-7.39% 1D
Market Cap $549.5M
TTM Revenue $161M
Forward P/E N/M
Beta / 30D Vol 2.25β · 104% Vol
Unified Composite Score
50.1 / 100 HOLD
Tech 40.0 Fund 55.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 35.4 · SMA20: $2.23 · SMA50: $2.05
VVOS NASDAQ
Vivos Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.05
-5.1% 1D
Market Cap $1.9M
TTM Revenue $21M
Forward P/E N/M
Beta / 30D Vol 1.70β · 111% Vol
Unified Composite Score
36.4 / 100 SELL
Tech 25.0 Fund 35.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.8%), weak momentum, RSI 19
RSI-14: 18.9 · SMA20: $0.10 · SMA50: $0.13

6-Pillar Scorecard Institutional Category Breakdown (PACB 2 – 3 VVOS)

Columns: Metric · PACB · VVOS
1. Valuation Multiples VVOS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 7.4x 0.1x
2. Growth & Scale PACB
Revenue Growth (YoY) +5.5% +34.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $161M $21M
Market Cap $549.5M $1.9M
3. Profitability & Quality VVOS
Gross Margin 27.7% 61.9%
Operating Margin -333.0% -107.9%
Net Profit Margin -81.3% -121.8%
Return on Equity (ROE) -929.3% -8585.3%
4. Balance Sheet & Cash Flow VVOS
Cash Generation (TTM) -$150M -$21M EBITDA
Cash Flow Margin -93.2% -99.3% EBITDA Mgn
Net Cash / Leverage $649M Net Debt -8585.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PACB
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 191.0% (97th %ile) N/A (N/A)
Put/Call OI Skew 0.07x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PACB (6) vs VVOS (2)
Institutional Metric PACB VVOS Criterion Row Edge
Market Capitalization
Scale
$549.5M $1.9M Larger Scale PACB
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+5.5% +34.9% Higher Growth VVOS
Operating Margin (TTM)
Profitability
-333.0% -107.9% Higher Margin VVOS
Net Profit Margin
Profitability
-81.3% -121.8% Higher Margin PACB
Return on Equity (ROE)
Capital Efficiency
-929.3% -8585.3% Higher ROE PACB
52-Week Range Position
Momentum
24% ($1–$3) 0% ($0–$3) Stronger Trend PACB
Beta / 30D Volatility
Risk Regime
2.25β · 104% Vol 1.70β · 111% Vol Lower Realized Risk PACB
Unified Institutional Score
Composite Signal
50.1 / 100 (HOLD) 36.4 / 100 (SELL) Higher Composite PACB
Trailing 12M Revenue (USD)
Operating Scale
$161M $21M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
27.7% 61.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 7.4x EV/Rev N/M PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$150M ($649M Net Debt) -$21M EBITDA (-8585.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PACB +38.38 pp
PACB: -20.87% · VVOS: -59.25%
3M Horizon PACB +107.83 pp
PACB: +27.34% · VVOS: -80.49%
6M Horizon PACB +124.76 pp
PACB: +33.61% · VVOS: -91.15%
1Y Horizon PACB +90.32 pp
PACB: -7.39% · VVOS: -97.71%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PACB Revenue VVOS Revenue PACB Op. Margin VVOS Op. Margin Margin Leader
FY2018 $80M N/A -128.4% N/A PACB
FY2019 $90M $10M -110.6% -92.8% VVOS
FY2020 $80M $10M -132.3% -92.1% VVOS
FY2021 $130M $20M -161.2% -120.7% VVOS
FY2022 $130M $20M -239.4% -156.2% VVOS
FY2023 $200M $10M -166.8% -125.3% VVOS
FY2024 $150M $20M -308.0% -74.3% VVOS
FY2025 $160M $20M -346.2% -114.1% VVOS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PACB BREAKDOWN
16d in phase · OBV DISTRIBUTION
Current IV 191.0%
IV Percentile 97th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact PACB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VVOS BREAKDOWN
113d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VVOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PACB Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $549.5M market capitalization and -333.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VVOS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.9M market capitalization and -107.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PACB vs VVOS Key Questions & Quantitative Answers

As of Nov 20, 2026, Pacific Biosciences of California, Inc. (PACB) captures the overall head-to-head institutional edge over Vivos Therapeutics, Inc. (VVOS) on higher Unified Composite conviction (50.1/100 HOLD vs. 36.4/100 SELL) after splitting the core matrix 6–2 (led by Growth & Scale, Options & Positioning), while VVOS wins 3–2 across the 6-pillar growth and valuation breakdown. PACB trades at $1.63 (N/M Forward P/E, -333.0% operating margin) versus VVOS at $0.05 (N/M Forward P/E, -107.9% operating margin). Growth vs. Quality Trade-Off: PACB earns the overall head-to-head edge with a stronger Unified Composite Score (50.1/100 HOLD vs. VVOS 36.4/100 SELL) and 2.25β · 104% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: PACB is currently in a Breakdown options structure phase (RSI 35.4); meanwhile VVOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PACB leads the Growth & Scale pillar: PACB posts +5.5% YoY revenue growth and +0.0% YoY earnings growth on $161M TTM revenue (27.7% gross margin, -333.0% operating margin), compared with VVOS at +34.9% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.9% gross margin, -107.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PACB cumulative revenue shifted +100.0% while VVOS shifted +100.0%. In operating R&D and SG&A reinvestment, PACB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VVOS.

VVOS screens cheaper on headline valuation multiples. PACB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-93.2% FCF margin), whereas VVOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-99.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PACB (-929.3% ROE) versus VVOS (-8585.3% ROE) capital efficiency.

In options market volatility and institutional positioning, PACB carries 191.0% implied volatility (97th %ile, Extreme (>80th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.25β · 104% Vol realized risk). By comparison, VVOS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 111% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.